- In May 2024, Novartis announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Scemblix (asciminib) for treating adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). This designation accelerates the drug's development and review process, offering hope for more effective treatment options for CML
- The World Health Organization (WHO) reported in 2024 that over 1 billion people globally are affected by neurological disorders, including Alzheimer's, Parkinson's, and stroke. These conditions are among the leading causes of disability worldwide, prompting urgent efforts in research and treatment innovation to manage these debilitating diseases effectively
